A Phase 4 interventional study of Bupivacaine Hydrochloride in Postoperative Pain Score, sponsored by Rajavithi Hospital. Completed at 1 site in Thailand. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-22.
Sponsored by Rajavithi Hospital · Phase 4, Interventional, and Treatment
To comparison of efficacy of Bupivacaine for relief postoperative pain in women undergoing laparoscopic gynecologic surgery
Gynecologic laparoscopic procedures have become more common nowadays because of their benefits in less tissue trauma, less perioperative morbidity and shorter hospital stays compared with laparotomy. But postoperative pain still be the most concerning problems including discomfort at incision sites, Pain due to pneumoperitoneum stretching the intraabdominal cavity and dissection of the abdominal and pelvic viscera.
Visceral pain is at maximal intensity during the first postoperative hours and is exacerbated by coughing, respiratory movements, and mobilization. Because the pain comprises of several factors, multimodal analgesic techniques are needed for effective postoperative analgesia and brought to this study to compare efficacy of Bupivacaine for pain relief postoperatively in women undergoing gynecologic laparoscopic surgery divided into 4 groups including preincision and preclosure Bupivacaine injection collated with placebo group. The result is measurement in postoperative pain score and amount of drug that using to reduce pain
Exclusion Criteria:
0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
Drug: Bupivacaine Hydrochloride
0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
Drug: Bupivacaine Hydrochloride
0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
Drug: Bupivacaine Hydrochloride
0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
Drug: Bupivacaine Hydrochloride
0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
Also known as: 0.5% Marcaine
Postoperative pain after surgery
Postoperative pain score in intervention and placebo groups
Time frame: 24-48 hours after surgery
Among of pethidine use
Among of pethidine use to reduced postoperative pain
Time frame: within 48 hours
Duration of hospital stay
Duration of hospital stay after surgery
Time frame: within 7 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rajavithi Hospital